[Clinical application of multiple fractions per day in lung and esophageal cancer]

We applied MFD to the treatment of forty-nine patients with lung and esophageal cancer. In lung cancer tumor response, tumor regression rate and local recurrence-free survival rate were higher in the MFD group. Although the actuarial survival rates in the two group were similar, the frequency of radiation pneumonitis was much lower in the MFD group. In esophageal cancer, the actuarial survival rate in the MFD group (49.8%) was significantly higher than that in the control group. (14.6%). However, the late effects of radiation were stricture in the 3.2 Gy/2f/day group. Further studies are needed to establish the optimal dose fractionation and indications for MFD therapy.